Annual Report

Overview

The report highlights continued development of the precision medicine Diamyd® in the registrational Phase 3 DIAGNODE-3 trial, including a positive interim analysis and a penultimate safety review. It reports Fast Track Designation for treatment across all stages of type 1 diabetes and describes progress at the Umeå GAD65 manufacturing facility. The sustainability section links the company's activities to SDGs 3, 9, 12 and 13 and discusses inclusive trial recruitment and sustainable manufacturing.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2024-2025
Period: 1 September 2024 – 31 August 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services